Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29876793 | 0.89 | NPC1 (0.57) | KMT2AMEN1TSHR | |
| SCHEMBL1762390 | 0.89 | CYP11B1 (0.57) | CYP11B1CYP11B2KMT2A | |
| SCHEMBL14305454 | 0.82 | CYP11B1 (0.54) | CYP11B1CYP11B2KMT2A | |
| SCHEMBL31472210 | 0.80 | NPC1 (0.40) | CYP11B1CYP11B2KMT2AMEN1TSHR | |
| SCHEMBL15841609 | 0.80 | CYP11B1 (0.68) | CYP11B1CYP11B2 | |
| SCHEMBL31472212 | 0.78 | NPC1 (0.45) | CYP11B1CYP11B2KMT2A | |
| SCHEMBL1762224 | 0.78 | CES1 (0.57) | CYP11B1CYP11B2 | |
| SCHEMBL10908994 | 0.78 | KMT2A (0.39) | CYP11B1CYP11B2KMT2AMEN1TSHR | |
| SCHEMBL6990481 | 0.76 | CYP11B1 (0.48) | CYP11B1CYP11B2KMT2A | |
| SCHEMBL31472073 | 0.76 | CYP11B1 (0.38) | CYP11B1CYP11B2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431365-A | Phenyl heterocyclic derivative-containing regulator and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2025026270-A1 | BENZO NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2025-02-06 | — | — | WO | disclosed |
| EP-3653618-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-01-08 | — | — | EP | disclosed |
| EP-3653618-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-05-20 | — | — | EP | disclosed |
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | disclosed |
| EP-2755963-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-20140187784-A1 | RADIOACTIVE QUINOLINONE DERIVATIVE AND PHARMACEUTICAL DRUG COMPRISING THE SAME | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2014-07-03 | — | — | US | disclosed |
| EP-2749561-A1 | Radioactive quinolinone derivative and pharmaceutical drug comprising the same | Kyoto University (JP) | 2014-07-02 | — | — | EP | disclosed |
| US-8541404-B2 | Inhibitors of the human aldosterone synthase CYP11B2 | ELEXOPHARM GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2280954-B1 | 6-PYRIDIN-3-YL-3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN ALDOSTERONE SYNTHASE CYP11B2 | UNIV SAARLAND (DE) | 2013-03-27 | — | — | EP | disclosed |
| WO-2013037779-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| US-20110118241-A1 | 6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187784-A1 | RADIOACTIVE QUINOLINONE DERIVATIVE AND PHARMACEUTICAL DRUG COMPRISING THE SAME | CYP11B2, CYP11B1, HSD11B1 | CYP11B1 2/4885CYP11B2 1/4885KMT2A 2519/4885 |
| US-20110118241-A1 | 6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2 | HSD11B1, HSD11B2, CYP4A11 | CYP11B1 6/4885CYP11B2 4/4885KMT2A 2403/4885 |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | HSD11B1, HSD11B2, CYP11B1 | CYP11B1 3/4885CYP11B2 4/4885KMT2A 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.